Disparities in Receipt of Adjuvant Immunotherapy among Stage III Melanoma Patients.

Autor: Mulligan KM; Case Western Reserve University School of Medicine., Kakish H; Department of Surgery, Division of Surgical Oncology., Pawar O; Department of Surgery., Ahmed FA; Department of Surgery, Division of Surgical Oncology., Elshami M; Department of Surgery, Division of Surgical Oncology., Rothermel LD; Department of Surgery, Division of Surgical Oncology., Bordeaux JS; Department of Dermatology, University Hospitals Cleveland Medical Center., Sheng IY; Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH., Mangla A; Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH., Hoehn RS; Department of Surgery, Division of Surgical Oncology.

Publikováno v: American journal of clinical oncology [Am J Clin Oncol] 2024 Nov 01; Vol. 47 (11), pp. 509-516. Date of Electronic Publication: 2024 Jun 28.

Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.

Autor: Nizam A; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Rader RK; Department of Medicine, Duke University, Durham, NC., Tzeng A; Department of Medicine, Brigham and Women's Hospital, Boston, MA., Wei W; Department of Quantitative Health Sciences, Cleveland Clinic Lerner Research Institute, Cleveland, OH., Sheng IY; Department of Hematology and Oncology, Beth Israel Lahey Health, Boston, MA., Martin A; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Wee CE; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Gilligan TD; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Gupta S; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH., Ornstein MC; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH. Electronic address: ornstem@ccf.org.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Apr; Vol. 22 (2), pp. 368-379. Date of Electronic Publication: 2023 Dec 15.

Author's Reply to Şener and Begijanashvili: "Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy".

Autor: Sheng IY; Department of Medicine, Beth Israel Lahey Mount Auburn Hospital, Boston, MA, USA., Khorana AA; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, 10201 Carnegie Ave/CA 60, Cleveland, OH, 44106, USA. khorana@ccf.org.

Publikováno v: Targeted oncology [Target Oncol] 2022 Jul; Vol. 17 (4), pp. 495-496. Date of Electronic Publication: 2022 Jul 11.

Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer.

Autor: Sheng IY; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Barata P; Department of Internal Medicine, Section of Hematology Oncology, Tulane University Medical School, New Orleans, LA, USA., Alameddine R; Department of Hematology Oncology, University Hospital Cleveland Medical Center, Cleveland, OH, USA., Garcia JA; Department of Hematology Oncology, University Hospital Cleveland Medical Center, Cleveland, OH, USA.

Publikováno v: Drugs in context [Drugs Context] 2021 Mar 15; Vol. 10. Date of Electronic Publication: 2021 Mar 15 (Print Publication: 2021).

Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone.

Autor: Sheng IY; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Fallah J; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Gupta R; Department of Hematology and Medical Oncology, Bellmunt Hospital, Troy, MI, USA., Li H; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Allman K; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Martin A; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Barata P; Department of Internal Medicine, Section of Hematology Oncology, Tulane University Medical School, New Orleans, LA, USA., Ornstein MC; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Gilligan TD; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Rini BI; Department of Internal Medicine, Section of Hematology Oncology, Vanderbilit University, Nashville, TN, USA., Garcia JA; Department of Hematology Oncology, University Hospital Cleveland Medical Center, Cleveland, OH, USA. Jorge.Garcia@UHhospitals.org.; Chair, Division of Solid Tumor Oncology, George and Edith Richman Distinguished Scientist Chair, Medicine and Urology, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Lakeside Suite 1200, Cleveland, OH, 44106, USA. Jorge.Garcia@UHhospitals.org.

Publikováno v: Targeted oncology [Target Oncol] 2020 Aug; Vol. 15 (4), pp. 477-483.